| Serial Number | 90039971 |
| Word Mark | ASCENTAGE PHARMA |
| Filing Date | Tuesday, July 7, 2020 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, November 23, 2021 |
| Registration Number | 6565245 |
| Registration Date | Tuesday, November 23, 2021 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, September 7, 2021 |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "PHARMA" |
| Description of Mark | The mark consists of a stylized letter "A", in the form of an open semi-circle comprised of two lines displayed in a semi-circular manner, one of which extends at the end to form a zig-zag pattern and an additional zig-zag shaped line displayed next to such zig-zag extension, all to the left of the word "ASCENTAGE PHARMA". |
| Goods and Services | Medicines for dental purposes; chemical preparations for medical purposes for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; medicine for injection for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicinal tablets, for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bulk drugs, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease sold in bulk; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories being pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; plasters for medical purposes; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; medicated candy; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic preparations adapted for medical use; oil solutions, namely, medicinal oils; mineral food supplements; nutritional supplements; medicines for human purposes, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for medical purposes for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemical preparations for pharmaceutical purposes, for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease |
| Goods and Services | Analysis of the mode of action of chemical combinations on animals; scientific research for medical purposes in the area of cancerous diseases; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical research services; scientific investigations for medical purposes; chemical analysis services; biochemical research and analysis; chemical research services; working on and evaluation of chemical analyses; chemical research and analysis; working on and evaluation of chemical syntheses; chemical analysis; chemistry services in the nature of chemist services; chemical research; cosmetics research; structural and functional analysis of genomes; stem cell research services; biotechnology research; blood analysis services; genetic screening for scientific research purposes; biological cloning services; research and development services in the field of antibodies; genetic testing for scientific research purposes; bacteriological research and analysis; biomedical research services; medical research; drug discovery services; medical laboratory services; development of pharmaceutical preparations and medicines; medical research services; biological research and analysis; bacteriological research; biological research; conducting clinical trials for others; computer programming in the medical field; pharmaceutical product evaluation; research on the subject of pharmaceuticals |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 4, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, August 4, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Jiangsu Ascentage Biomed Development Inc. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | Taizhou, Jiangsu 225300 CN |
| Party Name | Jiangsu Ascentage Biomed Development Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Taizhou, Jiangsu 225300 CN |
| Party Name | Jiangsu Ascentage Biomed Development Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Taizhou, Jiangsu 225300 CN |
| Event Date | Event Description |
| Tuesday, November 23, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, September 7, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 7, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, August 18, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, August 3, 2021 | ELECTRONIC RECORD REVIEW COMPLETE |
| Friday, July 30, 2021 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Wednesday, July 28, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, July 28, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, July 28, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, July 28, 2021 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Monday, April 12, 2021 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Monday, April 12, 2021 | FINAL REFUSAL E-MAILED |
| Monday, April 12, 2021 | FINAL REFUSAL WRITTEN |
| Tuesday, March 23, 2021 | ASSIGNED TO EXAMINER |
| Wednesday, February 3, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 3, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, February 2, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, October 20, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, October 20, 2020 | NON-FINAL ACTION E-MAILED |
| Tuesday, October 20, 2020 | NON-FINAL ACTION WRITTEN |
| Wednesday, October 14, 2020 | ASSIGNED TO EXAMINER |
| Wednesday, August 5, 2020 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Tuesday, August 4, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Monday, July 27, 2020 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Monday, July 27, 2020 | ASSIGNED TO LIE |
| Monday, July 13, 2020 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Friday, July 10, 2020 | NEW APPLICATION ENTERED IN TRAM |